Barclays’s AEON Biopharma AEON Stock Holding History

Barclays’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42	Buy	+59	New	+$49	﹤0.01%	5251
2025 Q4	–	Sell	-21	Closed	-$17	–	5204
2025 Q3	$17	Buy	+21	New	+$16	﹤0.01%	5368
2023 Q3	–	Sell	-3	Closed	-$1.37K	–	4581
2023 Q2	$1.37K	Hold	3	–	–	﹤0.01%	4343
2023 Q1	$1.97K	Sell	3 -283	-99%	-$205K	﹤0.01%	4892
2022 Q4	$207K	Hold	286	–	–	﹤0.01%	3822
2022 Q3	$203K	Buy	+286	New	+$203K	﹤0.01%	3195

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's AEON Position: Q2 2026 in Review

Barclays opened a new position in AEON Biopharma (AEON) in Q2 2026: 59 shares worth $42. The stake represents ﹤0.01% of the portfolio and ranks #5251 among its holdings. This is a return to the name: Barclays previously reported a position in AEON as recently as Q3 2025.

Barclays first reported a position in AEON in Q3 2022 and has held it in 6 quarters since. The position peaked at $207K in Q4 2022. 22 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

Barclays held 59 shares of AEON Biopharma worth $42 as of Q2 2026.
AEON Biopharma was a new Barclays position in Q2 2026.
AEON Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5251 holding.
Barclays first reported a position in AEON Biopharma in Q3 2022 and has held it in 6 quarters since.
Barclays's AEON Biopharma position peaked at $207K in Q4 2022.
22 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.